Anti-aging and pancreatic fibrosis therapeutic - Juventas Cell Therapy
Latest Information Update: 20 Feb 2026
At a glance
- Originator Juventas Cell Therapy
- Class Antifibrotics; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fibrosis; Unspecified
Most Recent Events
- 31 Dec 2025 Preclinical trials in Fibrosis in China (unspecified route), prior to December 2025 (Juventas Cell Therapy pipeline, December 2025)
- 31 Dec 2025 Preclinical trials in Unspecified in China (unspecified route), prior to December 2025 (Juventas Cell Therapy pipeline, December 2025)